What Is Thymalin?

1. Thymalin vs thymosin alpha-1 and Thymogen

Three related names refer to different preparations. Matching the name on a vial to the intervention in a paper comes before comparing benefits or milligrams.

A 2023 laboratory paper investigated Glu-Trp, abbreviated EW, and Lys-Glu, abbreviated KE, as active components of Thymalin. An isolated component and a complete extract are different experimental interventions. A synthetic product described only as “Thymalin peptide” needs a composition before you can judge whether a cited study applies to it.

The separate thymosin alpha-1 guide covers TA1’s clinical trials. A favorable TA1 result cannot supply missing evidence for Thymalin, and a negative TA1 trial does not settle Thymalin’s effects either.

2. How does thymalin work?

Researchers study thymalin as an immunomodulator: a preparation that changes immune activity. Two lines of work examine how immune cells mature and how much inflammatory signaling they produce.

In Khavinson and colleagues’ 2020 cell study, thymalin reduced expression of CD44 and CD117, markers associated with stem cells and intermediate stages of differentiation, by roughly two to three times. Expression of CD28 increased 6.8-fold. CD28 helps T cells receive activation signals.

The authors interpreted this pattern as indirect evidence of maturation toward T lymphocytes. A 6.8-fold change in a cell marker cannot be translated into “6.8 times stronger immunity.” The experiment did not count infections in people or image their thymus before and after treatment.

Linkova and colleagues’ 2023 study used computer modeling and blood cells from four donors. In an induced-inflammation model, thymalin and the EW and KE peptides reduced production of inflammatory signals including IL-1β, IL-6 and TNF-α. The reported reductions ranged from 1.4- to sixfold across experimental conditions.

These experiments help explain why researchers investigate both immune activation and control of inflammation. The proposed DNA interactions and gene targets remain mechanistic research. They do not establish that a course of injections resets gene expression to a younger state.

3. Thymalin longevity research: the mortality numbers

Khavinson and Morozov’s 2003 report covered 266 older people across two centers. Its St. Petersburg table reported:

The Thymalin comparison is a 40.1-percentage-point difference. The widely quoted 4.1-fold reduction comes from dividing 81.8% by 20.0% in the separate combination group. It does not mean four times longer life.

The initial groups were described as randomized and double-blind; allocation of the separate combination group was less clear. Small samples and limited methods reporting restrict interpretation.

Epithalamin is a pineal extract. Replacing it with synthetic Epitalon creates a different combination. This paper cannot validate a modern Thymalin–Epitalon stack.

4. Thymalin benefits: what do the infection studies show?

The recent human research includes hospitalized COVID-19 patients. These participants had an active disease and received other treatments, so the findings address a different question from preventing ordinary colds or improving training recovery.

In the first study, the percentages describe changes within the treated group. They are not a 63.8% reduction in infection risk. The full report also documents several additional drugs, with some treatments differing between groups. Open-label care and multiple therapies make the size of thymalin’s contribution harder to establish.

The second study adds a human clinical signal, but 80 hospitalized patients cannot establish year-round protection in healthy users. Neither study addresses persistent long-COVID fatigue, missed gym sessions or healthspan.

5. Thymalin dosage, cycles and half-life

The 92-patient COVID-19 study used 10 mg intramuscularly daily for five days alongside hospital treatment. That is a description of a study regimen. It does not establish a dose for immune maintenance or longevity.

The Russian medical product contains 10 mg of thymus extract and 20 mg of glycine per vial. The active extract and the total powder weight therefore differ. A vial labeled “10 mg” from another source does not, by that number alone, establish the same composition.

The sources reviewed here do not provide a dependable human elimination half-life for the whole mixture. Its components need not clear at the same rate. Borrowing TA1’s half-life, or entering an assumed value into a calculator, cannot establish when thymalin should be repeated.

Likewise, oral, nasal and subcutaneous products need evidence for their own absorption and effects. A milligram comparison cannot establish equivalent bioavailability. No study reviewed here validates a healthy-adult longevity cycle, repeat interval or combination with other research peptides.

6. Thymalin side effects and safety

The manufacturer’s instructions list allergic reactions and contraindications for individual intolerance, pregnancy and breastfeeding. They do not give an adverse-event frequency that would let a reader calculate a personal risk.

Small studies can miss uncommon harms. Long follow-up for survival also cannot substitute for systematic recording of adverse reactions, medication interactions and outcomes in people with different medical conditions. The evidence reviewed here does not resolve the safety of repeated self-directed courses.

Someone taking immunosuppressive medication needs their treating specialist to assess an immune-active preparation. The studies above cannot establish compatibility with an individual transplant, autoimmune or cancer-treatment regimen.

Product quality adds another uncertainty. An assay identifying a peptide does not establish that an injectable preparation is sterile or equivalent to the extract used in a trial. For a mixture, the identity and proportions of its components also matter. “99% purity” without a clear description of what was measured cannot answer those questions.

7. Is thymalin FDA approved?

Thymalin has no FDA-approved drug product. In a February 2024 warning letter to US Chem Labs, FDA identified the company’s thymalin product as an unapproved new drug and said it had not evaluated that product for safety, effectiveness or quality.

The agency also addressed the seller’s health claims despite its research-use labeling. A “research purposes” disclaimer does not turn a product marketed to treat disease into an approved medicine. The warning concerned that seller’s product; it was not a clinical trial of every thymalin preparation.

8. What would a meaningful improvement look like?

Define the outcome before interpreting a lab change. If the goal is fewer infections, relevant outcomes include the number of illness episodes, their duration and days of impaired function. If the goal is recovery, record the activities you could complete and the symptoms that limited them. A higher lymphocyte count alone does not answer either question.

Personal tracking has limits. Starting after an unusually bad month makes an ordinary return toward baseline easy to mistake for a treatment effect. Season, exposure to infections, vaccination, sleep and other medications can all complicate a before-and-after comparison. Adding several peptides together makes attribution harder still.

A useful record for a clinical discussion includes the exact preparation, dates, concurrent medications, symptoms and clinician-ordered measurements. Separate observations such as “two fewer sick days” from interpretations such as “my immune age reversed.” To test the latter claim, researchers would need a defined measure of immune aging and evidence that changing it improves health over time.

9. Thymalin FAQ

• What is thymalin used for?

  Thymalin is a thymus-derived peptide preparation used medically in Russia for specified immune-deficiency conditions. Research has examined immune markers, infection and aging. Those uses do not establish a benefit for healthy adults seeking better recovery or longer life.

• Is thymalin the same as thymosin alpha-1?

  No. Thymalin is an extract containing multiple peptides. Thymosin alpha-1 is a defined 28-amino-acid peptide, also called TA1; its synthetic form is thymalfasin. Their trials and doses are not interchangeable.

• Is thymalin a dipeptide?

  The original Thymalin preparation is a peptide mixture. Researchers have studied Glu-Trp and Lys-Glu among its components. A product containing one isolated dipeptide cannot automatically inherit the evidence for the full extract.

• Does thymalin reverse aging or regrow the thymus?

  Neither has been established in healthy people. Survival observations in older patients and changes in immune-cell markers cannot establish whole-body age reversal or thymus regrowth.

• What is the recommended thymalin dosage or cycle?

  There is no validated longevity cycle for healthy adults. Published research used intramuscular treatment in specific patient groups. Those regimens cannot establish equivalent effects from a different product or route.

• What is thymalin's half-life?

  The sources reviewed here do not establish a dependable human half-life for the whole preparation. Thymalin contains multiple peptides, and a half-life reported for TA1 or an isolated component cannot be assigned to the mixture.

• What side effects can thymalin cause?

  The manufacturer's Russian instructions list allergic reactions and contraindicate use during pregnancy and breastfeeding or with individual intolerance. The available studies cannot quantify every risk of repeated use.

• Is thymalin FDA approved?

  Thymalin has no FDA-approved drug product. In 2024, FDA warned US Chem Labs that its thymalin product was an unapproved new drug. Russian medical use does not establish US approval.

10. Sources